Tag: Madrigal Pharmaceuticals

January 2, 2020

Biotech Outlook 2020: Washington Scrutiny Looms Over Sector

INN offers a closer look at the path ahead for biotech investors in 2020 as new challenges arise for the...
June 7, 2018

Madrigal Pharmaceuticals Prices Public Offering of Common Stock

Madrigal Pharmaceuticals (Nasdaq:MDGL), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutic candidates for the treatment...
June 6, 2018

Madrigal Pharmaceuticals Announces Proposed Public Offering of Common Stock

Madrigal Pharmaceuticals (Nasdaq:MDGL), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutic candidates for the treatment...
May 8, 2018

Madrigal Pharmaceuticals Reports 2018 First Quarter Financial Results and Reviews Key Clinical Achievements

Madrigal Pharmaceuticals (NASDAQ:MDGL) today announced its first quarter 2018 financial results. As quoted in the press release: “The results to...
April 24, 2018

Pharmaceutical Update: Q1 in Review

What happened in Q1 2018 for the pharma industry? Here's a look back at some of the quarter's biggest news...
February 8, 2018

Madrigal’s MGL-3196 Achieves Primary Endpoint in Patients with Heterozygous Familial Hypercholesterolemia

Madrigal Pharmaceuticals, (NASDAQ:MDGL) today announced positive results from a double-blind, placebo-controlled, multi-center, 12-week Phase 2 clinical trial in patients with...
February 8, 2018

Madrigal’s MGL-3196 Achieves Primary Endpoint in Patients with Heterozygous Familial Hypercholesterolemia

Madrigal Pharmaceuticals (NASDAQ:MDGL) announced positive results from a double-blind, placebo-controlled, multi-center, 12-week Phase 2 clinical trial in patients with heterozygous...